T. Rowe Price Associates
RLAY icon

T. Rowe Price Associates’s Relay Therapeutics RLAY Stock Holding History

T. Rowe Price Associates’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144M Buy
7,708,507
+5,783,569
+300% +$84M 0.01% 601
2026
Q1 		$19.2M Buy
1,924,938
+279,535
+17% +$2.5M ﹤0.01% 1050
2025
Q4 		$13.9M Buy
1,645,403
+507,722
+45% +$3.62M ﹤0.01% 1157
2025
Q3 		$5.94M Sell
1,137,681
-1,738,255
-60% -$6.63M ﹤0.01% 1350
2025
Q2 		$9.95M Sell
2,875,936
-601,855
-17% -$1.79M ﹤0.01% 1115
2025
Q1 		$9.11M Buy
3,477,791
+156,050
+5% +$611K ﹤0.01% 1132
2024
Q4 		$13.7M Sell
3,321,741
-1,958,550
-37% -$10.7M ﹤0.01% 1076
2024
Q3 		$37.4M Buy
5,280,291
+241,276
+5% +$1.8M ﹤0.01% 831
2024
Q2 		$32.9M Sell
5,039,015
-1,840,582
-27% -$12.6M ﹤0.01% 836
2024
Q1 		$57.1M Sell
6,879,597
-1,701,570
-20% -$16.6M 0.01% 694
2023
Q4 		$94.5M Sell
8,581,167
-27,779
-0.3% -$234K 0.01% 561
2023
Q3 		$72.4M Buy
8,608,946
+263,429
+3% +$2.83M 0.01% 577
2023
Q2 		$105M Buy
8,345,517
+1,482,557
+22% +$18.4M 0.01% 515
2023
Q1 		$113M Buy
6,862,960
+2,369,956
+53% +$42.5M 0.02% 487
2022
Q4 		$67.1M Sell
4,493,004
-68,359
-1% -$1.31M 0.01% 584
2022
Q3 		$102M Sell
4,561,363
-738,944
-14% -$16.2M 0.02% 485
2022
Q2 		$88.8M Buy
5,300,307
+300,589
+6% +$6.44M 0.01% 698
2022
Q1 		$150M Buy
4,999,718
+844,377
+20% +$20.5M 0.02% 615
2021
Q4 		$128M Buy
4,155,341
+2,537,388
+157% +$80.2M 0.01% 694
2021
Q3 		$51M Buy
1,617,953
+444,471
+38% +$15M ﹤0.01% 1003
2021
Q2 		$42.9M Sell
1,173,482
-331,610
-22% -$10.9M ﹤0.01% 1082
2021
Q1 		$52M Buy
1,505,092
+731,517
+95% +$31.7M 0.01% 989
2020
Q4 		$32.1M Sell
773,575
-13,927
-2% -$630K ﹤0.01% 1092
2020
Q3 		$33.5M Buy
+787,502
New +$30M ﹤0.01% 1002

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

T. Rowe Price Associates's RLAY Position: Q2 2026 in Review

T. Rowe Price Associates increased its Relay Therapeutics (RLAY) stake by 300% in Q2 2026, buying an estimated $84M and bringing the position to 7,708,507 shares worth $144M. The position accounts for 0.01% of the portfolio, ranked #601.

T. Rowe Price Associates first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. The position peaked at $150M in Q1 2022. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • T. Rowe Price Associates held 7,708,507 shares of Relay Therapeutics worth $144M as of Q2 2026.
  • T. Rowe Price Associates bought 5,783,569 Relay Therapeutics shares in Q2 2026, an estimated $84M.
  • Relay Therapeutics made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #601 holding.
  • T. Rowe Price Associates first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • T. Rowe Price Associates's Relay Therapeutics position peaked at $150M in Q1 2022.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.